Gastrointestinal Very common (10% or more): Gastrointestinal adverse reactions (up to 73%), nausea (up to 44%), vomiting (up to 36%), diarrhea (up to 30%), constipation (up to 24.2%), abdominal pain (up to 20%) Common (1% to 10%): Dyspepsia, abdominal distension, eructation, flatulence, gastroenteritis, gastroesophageal reflux disease, gastritis, viral gastroenteritis, increased amylase, increased lipase, dry mouth, severe gastrointestinal adverse reactions, delayed gastric emptying Uncommon (0.1% to 1%): Acute pancreatitis, appendicitis Frequency not reported : Hemorrhoids, hiccups Postmarketing reports : Ileus, intestinal obstruction, severe constipation, hiccups, acute pancreatitis, necrotizing pancreatitis In clinical trials in adults using the subcutaneous injection for weight reduction, 73% of treated patients reported gastrointestinal adverse reactions, including severe reactions (4.1%)
PT-141 may not fix severe blood flow issues by itself
-
This process is also important not just for athletes, but also to anyone wanting to support general health, enhance energy, or boost heart performance
Formulary prescriptions are included in a plans drug list and paid for by the plan
Potential Kidney Issues : Monitoring kidney function is critical, particularly for those with pre-existing kidney conditions
